Protagonist Therapeutics (NASDAQ:PTGX) has announced its participation in the BTIG Virtual Biotechnology Conference 2024. The event is scheduled for August 5-6, 2024. The company’s President and CEO, Dr. Dinesh V. Patel, will participate in a fireside chat on Tuesday, August 6 from 2:00 PM to 2:35 PM EDT.
In addition to fireside chats, the Protagonist team will also be available for one-on-one meetings during the conference. If you’re interested, please reach out to your BTIG representative to arrange a meeting with the Protagonist team.
Protagonist Therapeutics (NASDAQ:PTGX) has announced that it will participate in the BTIG Virtual Biotechnology Conference 2024. The event will take place on or before May 6, 2024. Dr. Dinesh V. Patel, President and CEO will be in attendance. 6 days ago 14:00 PM 14:35 EDT.
During the meeting, everything must be decided informally and the protagonist team must decide separately. The Parti interessete sono will invite each unrelated organization in the protagonist team to report directly to BTIG.
Protagonist Therapeutics (NASDAQ:PTGX) has announced its participation in the virtual Biotechnology BTIG 2024 conference, with the event program taking place on May 6, 2024, with Dinesh V. Patel, PhD, President and CEO, and informal attendees from 2:00 to 2:35 PM EDT six days prior.
Adémas de la Chara, El equipo de protagonista Estara, will be available to participate in personal alumni events during the conference and will maintain ties with protagonists as representatives of the BTIG Para-sponsored alumni association.
Protagonist Therapeutics (NASDAQ:PTGX) joined BTIG and saw its stock price increase in 2024. It is August 5th and 6th, 2024. Dinesh V. Patel CEO Dinesh V. Patel It’s a good idea.
I want to know what I want to know. The main character is BTIG.
Protagonist Therapeutics (NASDAQ:PTGX) announces its participation at the BTIG 2024 Conference Virtuelle de Biotechnology, scheduled for May and 6, 2024. Dr. Dinesh V. Patel, President and Entrepreneur PDG, will be participating in the discussion from 14:00 to 14:35 EDT Mardi time.
In addition to the discussion, the protagonists will need to continue to meet individually, with the participants being the contact representative from BTIG inviting the organizer as the host and inviting the protagonists.
Protagonist Therapeutics (NASDAQ:PTGX) will participate in the BTIG Virtual Biotechnology Conference 2024. View statistics for 5th and 6th August 2024. Dinesh V. Patel, Ph.D., President and CEO of the Organization, will be present at the 6th August from 14:00 to 14:35 EDT to inform you of any unforeseen circumstances.
The team’s heroes provide the information needed to make a decision on the Einzelgespreche. Interested parties should contact their BTIG partners and have a meeting with the hero team.
July 22, 2024 – 7:00 AM
NEWARK, CA / ACCESSWIRE / July 22, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) (“Protagonist” or the “Company”) today announced that Dr. Dinesh V. Patel, President and Chief Executive Officer, will participate in fireside chats and one-on-one meetings at the BTIG Virtual Biotechnology Conference.
BTIG Virtual Biotechnology Conference – August 5-6, 2024
Format: Fireside chat
Date and Time: Tuesday, August 6th, 2:00pm-2:35pm EDT
If you’re interested in meeting the Protagonist team during the conference, please reach out to your BTIG representative.
About the protagonist
Protagonist Therapeutics is a biopharmaceutical company with two peptide-based new chemical entities (NCEs), lasfeltide and JNJ-2113 (formerly PN-235), derived from the company’s proprietary technology platform. Both entities have progressed to the Phase 3 stage of clinical development. Protagonist and JNJ scientists jointly discovered PN-235 as part of an interleukin-23 receptor (IL-23R) antagonist collaboration with JNJ and conducted IND-enabling preclinical and Phase 1 studies. JNJ is responsible for further clinical development. Lasfeltide, a mimetic of the natural hormone hepcidin, is the company’s lead drug candidate currently in a global Phase 3 development program for polycythemia vera (PV). The randomized portion of the Phase 2 REVIVE trial has been successfully completed, with results published in The New England Journal of Medicine in February 2024. The open-label extension (OLE) portion of the Phase 2 REVIVE trial is ongoing, followed by an additional two-year long-term extension (LTE) THRIVE trial. Enrollment has been completed in the international Phase 3 VERIFY trial of lasfeltide in polycythemia vera. Lasfeltide is being co-developed and co-commercialized with Takeda under a worldwide collaboration and license agreement with Takeda announced in January 2024.
More information about Protagonist and its pipeline drug candidates and clinical trials can be found on the company’s website at www.protagonist-inc.com
Investor Relations Contact
Dr. Corey Davis
Life Sciences Advisor
+1 212 915 2577
inquiry
Media Contact
Virginia Ammann, Founder and CEO
ENTENTE Corporate Network
virginiaammann@ententeinc.com
Source: Protagonist Therapeutics, Inc.
View the original press release at accesswire.com
FAQ
When will Protagonist Therapeutics (PTGX) participate in the BTIG Virtual Biotechnology Conference 2024?
Protagonist Therapeutics (PTGX) will participate in the BTIG Virtual Biotechnology Conference, taking place August 5-6, 2024. The company’s Fireside Chat is scheduled for Tuesday, August 6, from 2:00 PM to 2:35 PM EDT.
Who will be representing Protagonist Therapeutics (PTGX) at the BTIG Virtual Biotech Conference 2024?
Protagonist Therapeutics’ President and CEO, Dinesh V. Patel, PhD, will represent the company at the BTIG Virtual Biotechnology Conference 2024.
What will Protagonist Therapeutics (PTGX) be presenting at the BTIG Virtual Biotechnology Conference 2024?
Protagonist Therapeutics (PTGX) will participate in a fireside chat style presentation at the BTIG Virtual Biotechnology Conference 2024.
How can investors arrange a meeting with Protagonist Therapeutics (PTGX) during the BTIG Virtual Biotech Conference 2024?
Investors interested in meeting with the Protagonist Therapeutics team during the conference should contact their BTIG representative to arrange a one-on-one meeting.
